Oracle stock falls after report reveals thin margins in AI cloud business
Aardvark Therapeutics (NASDAQ:AARD) Chief Financial Officer Nelson Sun reported purchasing 6,000 shares of common stock on September 9, 2025. The purchases were executed at prices ranging from $8.00 to $8.20, averaging $8.0733 per share, for a total transaction value of $48,439. The transaction occurred near the stock’s current trading price of $8.00, with InvestingPro analysis indicating the shares are slightly overvalued at current levels.
Following the transaction, Sun directly owns 105,484 shares of Aardvark Therapeutics . The insider purchase comes as the company, currently valued at $172 million, maintains a strong liquidity position with more cash than debt on its balance sheet. InvestingPro analysis reveals 8 additional key insights about AARD’s financial health and future prospects, available to subscribers.
In other recent news, Aardvark Therapeutics has reported promising preclinical results for its investigational drug ARD-201, which demonstrated approximately 19% body weight reduction in diet-induced obese mice over 30 days. The company noted that ARD-201 also helped prevent weight regain after discontinuation of tirzepatide, a GLP-1 receptor agonist. Meanwhile, Cantor Fitzgerald has reiterated its Overweight rating for Aardvark Therapeutics, maintaining a $50.00 price target and emphasizing the potential undervaluation of the company’s market capitalization. RBC Capital, however, adjusted its price target for Aardvark Therapeutics to $19.00, citing delays in the company’s clinical timelines, particularly the postponement of the Phase III trial for its ’101 drug in Prader-Willi syndrome to the third quarter of 2026. H.C. Wainwright has initiated coverage on the company with a Buy rating and a $40.00 price target, highlighting Aardvark’s novel approach in treating obesity and hyperphagic conditions. The firm’s lead candidate, ARD-101, is noted for its unique mechanism of action involving gut receptors. These recent developments offer a range of insights into the company’s ongoing projects and market evaluations.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.